US Supreme Court saves Teva $500 million

Generic-drug labels need not warn of side effects if those on original drug don’t.

June 24, 2011 04:53
2 minute read.
US Supreme Court saves Teva $500 million

Teva. (photo credit: Ariel Jerozolimski)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceutical Industries Ltd. won a legal victory in the United States on Thursday worth about $500 million to the company. By a majority of five to four, the US Supreme Court ruled that generic-drug companies cannot be sued under state law over allegations they failed to provide adequate label warnings about potential side effects.

In the lawsuit filed against Actavis and Pliva, the Supreme Court ruled that makers of generic drugs did not have to warn of side effects of drugs on their labels, as long as the maker of the original drug did not do so.

Be the first to know - Join our Facebook page.

The Supreme Court thus overturned an Appeals Court decision allowing the lawsuit to proceed. The latest decision represents a victory for Teva, Mylan Inc. unit UDL Laboratories and Icelandic company Actavis Inc.

The generic-drug companies argued that federal law did not allow such lawsuits, since the drugs were approved by the US Food and Drug Administration.

They said federal law required that labeling of generic drugs should be the same as for the equivalent ethical drug.

In May 2010, Teva lost in a suit involving the same question, when a Nevada court ruled that it must pay compensation of $256m. It also ruled that Baxter Healthcare, which distributed the anaesthetic propofol, produced by Teva, must pay compensation of $144m. to a patient anaesthetized using the injection.

The propofol vials were reused at clinics in Nevada, leading to an outbreak of hepatitis C. The court found that the labels on the drug had failed to warn against reuse.

The current Supreme Court decision overturns the ruling, saving Teva from having to make a huge payout.

Generic drugs account for about 70 percent of drugs prescribed in the US.

“Teva is pleased with the High Court’s decision [Thursday], which provides great clarity for both the drug industry as well as patients,” Teva said in a statement.

“This ruling reiterates that once the US Food and Drug Administration approves a generic prescription drug as interchangeable to the brand, their labels must also be identical in all material respects.

“Accordingly, generic companies do not have the ability to influence labeling and related information and should not be held liable for failing to do so.

This is also a win for American consumers, as they bear the ultimate burden of these lawsuits. The decision of the Supreme Court will help to alleviate unnecessary litigation.”

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection